Clinical trial NCT02444884: MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors
Official title: A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Unspecified Childhood Solid Tumor, Excluding CNS
Neuroblastoma
Lead sponsor: Children's Oncology Group
Sponsor class: NETWORK
Collaborators: name: National Cancer Institute (NCI)
First posted: 2015-05-15
Enrollment: 54
Sex: ALL
Minimum age (years): 12
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: RATIONALE: MLN8237 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I/II trial is studying the side effects and best dose of MLN8237 and to see how well it works in treating young patients with relapsed or refractory solid tumors

Detailed description: 1.1 Primary Aims 1.1.1 To estimate the maximum tolerated dose (MTD) and recommended Phase II dose of MLN8237 administered orally once daily for 7 days every 21 days to children with refractory solid tumors. 1.1.2 To estimate the maximum tolerated dose (MTD) and recommended Phase II dose of MLN8237 administered orally twice daily for 7 days every 21 days to children with refractory solid tumors. 1.1.3 To define and describe the toxicities of MLN8237 administered on this schedule.

1.1.4 To characterize the pharmacokinetics of MLN8237 in children with refractory cancer.

1.2 Secondary Aims 1.2.1 To preliminarily define the antitumor activity of MLN8237 within the confines of a Phase I study. 1.2.2 To obtain initial Phase II efficacy data on the anti-tumor activity of MLN8237 in children with relapsed-refractory neuroblastoma using the once daily dosing schedule. 1.2.3 To explore the relationship between polymorphic variations in the UDPglucuronyltransferase gene UGT1A1 and exposure to MLN8237.

1.2.4 To assess two common polymorphic variants in the Aurora A kinase gene (Phe31Ile and Val57Ile) thought to potentially influence tumorigenesis. 1.2.5 To preliminarily examine the relationsh

Eligibility criteria: Inclusion Criteria:

* Diagnosis: Patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of CSF or serum tumor markers including alpha-fetaprotein or beta-HCG.
* Performance Level: Karnofsky \>/= 50% for patients \> 16 years of age and Lansky

  \>/= 50 for patients \</=16 years of age
* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
* Adequate Bone Marrow Function Defined as:

  a. For patients with solid tumors:
* Peripheral absolute neutrophil count (ANC) \>/= 1000/microLiter
* Platelet count \>/= 100,000/microLiter (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
* Hemoglobin \>/= 8.0 g/dL (may receive RBC transfusions)
* Creatinine clearance or radioisotope GFR \>/= 70ml/min/1.73 m2
* Bilirubin (sum of conjugated + unconjugated) \</= 1.5 x upper limit of normal (ULN) for age, and
* SGPT (ALT) \</= 5.0 x ULN for age (≤ 225 U/L). For the purpose of this study, the ULN for SGPT is 45 U/L.
* Serum albumin \>/= 2 g/dL.

Exclusion Criteria:

* Pregnant or breast-feeding women will not be entered on this study
* Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment.
* Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the prior 7 days are not eligible.
* Patients who are currently receiving another investigational drug are not eligible.
* Patients who are currently receiving other anticancer agents, digoxin, cyclosporine, tacrolimus or sirolimus, use of daily benzodiazepines are not eligible
* Patients who have an uncontrolled infection are not eligible.

Primary outcomes:
measure: Determine maximum tolerated dose and RP2D administered once daily on Days 1-7
timeFrame: Up to 21 days (1st cycle) of protocol therapy
measure: Determine maximum tolerated dose and RP2D administered po BID on Days 1-7
timeFrame: Up to 21 days (1st cycle) of protocol therapy
measure: Adverse events as assessed by (CTCAE) version 4.0
timeFrame: Every 21 days (each cycle) of protocol therapy for up to 35 cycles [up to 105 weeks]
measure: PK Profile: MLN8237 concentrations in plasma samples
timeFrame: 30 min after the first dose, and at 1,2, 3, 4, 6-8, 24 hours, Day 4 and 7 in Cycle 1
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Zhou X, Mould DR, Yuan Y, Fox E, Greengard E, Faller DV, Venkatakrishnan K. Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. J Clin Pharmacol. 2022 Feb;62(2):206-219. doi: 10.1002/jcph.1958. Epub 2022 Jan 15.